利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

22 条记录 (耗时 0.029 秒)

    Co-culture of placental stem cells and stem cells from a second source
    1.
    发明授权
    Co-culture of placental stem cells and stem cells from a second source 有权
    来自第二来源的胎盘干细胞和干细胞的共培养

    公开(公告)号：US07700090B2

    公开(公告)日：2010-04-20

    申请号：US11648802

    申请日：2006-12-28

    申请人： Mohammad Heidaran ,  Jia-Lun Wang ,  Qian Ye ,  Andrew Zeitlin ,  Colleen Suzanne Dulaney

    发明人： Mohammad Heidaran ,  Jia-Lun Wang ,  Qian Ye ,  Andrew Zeitlin ,  Colleen Suzanne Dulaney

    IPC分类号： A01N63/00 ,  A61K35/50

    CPC分类号： C12N5/0647 ,  A61K35/50 ,  A61K35/51 ,  A61K2035/124 ,  C12N5/0605 ,  C12N2502/02 ,  C12N2502/025 ,  G01N33/56966

    摘要： The present invention relates to a combination of placental stem cells and stem or progenitor cells derived from a second source, wherein the combination shows improved engraftment as compared to placental stem cells or stem cells from a second source, alone. The combination is referred to as a combined stem cell population. The invention also provides in vitro and in vivo methods for identifying and producing combined stem cell populations, and models of engraftment. In accordance with the present invention, the placental stem cells may be combined with, e.g., umbilical cord blood-derived stem or progenitor cells, fetal or neonatal stem cells or progenitor cells, adult stem cells or progenitor cells, hematopoietic stem cells or progenitor cells, stem or progenitor cells derived from bone marrow, etc.

    摘要翻译： 本发明涉及胎盘干细胞和衍生自第二来源的干细胞或祖细胞的组合，其中与来自第二来源的胎盘干细胞或干细胞相比，该组合显示出改善的植入。 该组合被称为组合干细胞群体。 本发明还提供用于鉴定和产生组合的干细胞群体和植入模型的体外和体内方法。 根据本发明，胎盘干细胞可与例如脐带血衍生的干细胞或祖细胞，胎儿或新生儿干细胞或祖细胞，成体干细胞或祖细胞，造血干细胞或祖细胞 ，源自骨髓的干细胞或祖细胞等

    Co-culture of placental stem cells and stem cells from a second source
    2.
    发明申请
    Co-culture of placental stem cells and stem cells from a second source 审中-公开
    来自第二来源的胎盘干细胞和干细胞的共培养

    公开(公告)号：US20080175824A1

    公开(公告)日：2008-07-24

    申请号：US11982211

    申请日：2007-10-31

    申请人： Mohammad Heidaran ,  Jia-Lun Wang ,  Qian Ye ,  Andrew Zeitlin ,  Colleen Suzanne Dulaney

    发明人： Mohammad Heidaran ,  Jia-Lun Wang ,  Qian Ye ,  Andrew Zeitlin ,  Colleen Suzanne Dulaney

    IPC分类号： A61K35/12 ,  C12N5/08

    CPC分类号： C12N5/0647 ,  A61K35/50 ,  A61K35/51 ,  A61K2035/124 ,  C12N5/0605 ,  C12N2502/02 ,  C12N2502/025 ,  G01N33/56966

    摘要： The present invention relates to a combination of placental stem cells and stem or progenitor cells derived from a second source, wherein the combination shows improved engraftment as compared to placental stem cells or stem cells from a second source, alone. The combination is referred to as a combined stem cell population. The invention also provides in vitro and in vivo methods for identifying and producing combined stem cell populations, and models of engraftment. In accordance with the present invention, the placental stem cells may be combined with, e.g., umbilical cord blood-derived stem or progenitor cells, fetal or neonatal stem cells or progenitor cells, adult stem cells or progenitor cells, hematopoietic stem cells or progenitor cells, stem or progenitor cells derived from bone marrow, etc.

    摘要翻译： 本发明涉及胎盘干细胞和衍生自第二来源的干细胞或祖细胞的组合，其中与来自第二来源的胎盘干细胞或干细胞相比，该组合显示出改善的植入。 该组合被称为组合干细胞群体。 本发明还提供用于鉴定和产生组合的干细胞群体和植入模型的体外和体内方法。 根据本发明，胎盘干细胞可以与例如脐带血衍生的干细胞或祖细胞，胎儿或新生儿干细胞或祖细胞，成体干细胞或祖细胞，造血干细胞或祖细胞 ，源自骨髓的干细胞或祖细胞等

    Co-culture of placental stem cells and stem cells from a second source
    3.
    发明申请
    Co-culture of placental stem cells and stem cells from a second source 有权
    来自第二来源的胎盘干细胞和干细胞的共培养

    公开(公告)号：US20070292910A1

    公开(公告)日：2007-12-20

    申请号：US11648824

    申请日：2006-12-28

    申请人： Mohammad Heidaran ,  Jia-Lun Wang ,  Qian Ye ,  Andrew Zeitlin ,  Colleen Dulaney

    发明人： Mohammad Heidaran ,  Jia-Lun Wang ,  Qian Ye ,  Andrew Zeitlin ,  Colleen Dulaney

    IPC分类号： C12N5/08 ,  C12Q1/02

    CPC分类号： C12N5/0647 ,  A61K35/50 ,  A61K35/51 ,  A61K2035/124 ,  C12N5/0605 ,  C12N2502/02 ,  C12N2502/025 ,  G01N33/56966

    摘要： The present invention relates to a combination of placental stem cells and stem or progenitor cells derived from a second source, wherein the combination shows improved engraftment as compared to placental stem cells or stem cells from a second source, alone. The combination is referred to as a combined stem cell population. The invention also provides in vitro and in vivo methods for identifying and producing combined stem cell populations, and models of engraftment. In accordance with the present invention, the placental stem cells may be combined with, e.g., umbilical cord blood-derived stem or progenitor cells, fetal or neonatal stem cells or progenitor cells, adult stem cells or progenitor cells, hematopoietic stem cells or progenitor cells, stem or progenitor cells derived from bone marrow, etc.

    摘要翻译： 本发明涉及胎盘干细胞和衍生自第二来源的干细胞或祖细胞的组合，其中与来自第二来源的胎盘干细胞或干细胞相比，该组合显示出改善的植入。 该组合被称为组合干细胞群体。 本发明还提供用于鉴定和产生组合的干细胞群体和植入模型的体外和体内方法。 根据本发明，胎盘干细胞可与例如脐带血衍生的干细胞或祖细胞，胎儿或新生儿干细胞或祖细胞，成体干细胞或祖细胞，造血干细胞或祖细胞 ，源自骨髓的干细胞或祖细胞等

    Methods of using thalidomide in combination with irinotecan
    4.
    发明申请
    Methods of using thalidomide in combination with irinotecan 失效
    沙利度胺联合伊立替康的方法

    公开(公告)号：US20050203060A1

    公开(公告)日：2005-09-15

    申请号：US11126315

    申请日：2005-05-11

    申请人： Rangaswamy Govindarajan ,  Andrew Zeitlin

    发明人： Rangaswamy Govindarajan ,  Andrew Zeitlin

    IPC分类号： A61K31/445 ,  A61K31/454 ,  A61K31/47 ,  A61K31/4745 ,  A61K31/724 ,  A61P35/00 ,  A61P35/04 ,  A61P43/00

    CPC分类号： A61K31/47 ,  A61K31/445 ,  A61K31/454 ,  A61K31/4745 ,  A61K31/724 ,  A61K2300/00

    摘要： This invention relates to compositions comprising thalidomide and irinotecan, which can be used in the treatment or prevention of colorectal cancer. The invention also relates to methods of treating or preventing colorectal cancer which comprise the administration of thalidomide and irinotecan to a patient in need of such treatment or prevention. The invention further relates to methods of reducing or avoiding adverse side effects associated with the administration of irinotecan which comprise the administration of thalidomide to a patient in need of such reduction or avoidance.

    摘要翻译： 本发明涉及可用于治疗或预防结肠直肠癌的沙利度胺和伊立替康的组合物。 本发明还涉及治疗或预防结直肠癌的方法，其包括向需要这种治疗或预​​防的患者施用沙利度胺和伊立替康。 本发明还涉及减少或避免与施用伊立替康有关的不良副作用的方法，其包括向需要这种还原或避免的患者施用沙利度胺。

    Compositions and methods for the treatment of cancer
    5.
    发明申请
    Compositions and methods for the treatment of cancer 审中-公开
    用于治疗癌症的组合物和方法

    公开(公告)号：US20050148524A1

    公开(公告)日：2005-07-07

    申请号：US11074849

    申请日：2005-03-09

    申请人： Jerome Zeldis ,  Andrew Zeitlin ,  Sol Barer

    发明人： Jerome Zeldis ,  Andrew Zeitlin ,  Sol Barer

    IPC分类号： A61K45/00 ,  A61K31/454 ,  A61K31/47 ,  A61K31/4745 ,  A61K31/7056 ,  A61K31/724 ,  A61P35/00 ,  A61P43/00 ,  A61K31/7052

    CPC分类号： A61K31/4745 ,  A61K31/454 ,  A61K31/47 ,  A61K31/7056 ,  A61K31/724 ,  A61K31/445 ,  A61K2300/00

    摘要： This invention relates to compositions comprising thalidomide and another anti-cancer drug which can be used in the treatment or prevention of cancer. Preferred anti-cancer drugs are topoisomerase inhibitors. A particular composition comprises thalidomide, or a pharmaceutically acceptable salt, solvate, or clathrate thereof, and irinotecan. The invention also relates to methods of treating or preventing cancer which comprise the administration of a thalidomide and another anti-cancer drug to a patient in need of such treatment or prevention. The invention further relates to methods of reducing or avoiding adverse side effects associated with the administration of chemotherapy or radiation therapy which comprise the administration of thalidomide to a patient in need of such reduction or avoidance.

    摘要翻译： 本发明涉及可用于治疗或预防癌症的沙利度胺和另一种抗癌药物的组合物。 优选的抗癌药物是拓扑异构酶抑制剂。 特定组合物包含沙利度胺或其药学上可接受的盐，溶剂合物或包合物和伊立替康。 本发明还涉及治疗或预防癌症的方法，其包括向需要这种治疗或预​​防的患者施用沙利度胺和另一种抗癌药物。 本发明还涉及减少或避免与化疗或放射治疗相关的不良副作用的方法，其包括向需要这种减少或避免的患者施用沙利度胺。